
Vita
Prof. Dr. med. Johannes Mann
Berufliche Entwicklung
Training and professional activities
1968-1974
Medical School in Germany and in France
1974
M.D., University of Heidelberg, Germany
1974-1976
Intern, Univ. of Heidelberg and of Kiel
1976-1978
Reseach fellow, Dept. of Pharmacology, Univ. of Heidelberg (with F. Gross and D. Ganten)
1978-1980
Senior research fellow, Clinical Research Institute of Montréal, Univ. of Montréal & McGill, Canada (with J. Genest)
1980-1985
Resident and senior resident, Depts. of Medicine and of Nephrology, Univ. of Heidelberg (with E. Ritz)
1985-1989
Staff member and assistant professor of Medicine, Dept. of Medicine, Univ. of Heidelberg
1989-1992
Professor of Medicine and of Pharmacology, Univ. of Erlangen-Nuremberg, vice-chairman, Dept. of Nephrology
1992- today
Director, Dept. of Nephrology, Schwabing General Hospital at Munich and KfH Kidney Center, Schwabing, Munich, Professor of Medicine, Univers. of Erlangen-Nürnberg
Medical degrees
Board certified specialist (Facharzt) for
Pharmacology and Toxicology (1982),
Internal Medicine (1985), Nephrology (1986),
Intensive Care (1995)
Main research activities
Experimental:
Angiotensin and renal damage,
Physiology of vascular angiotensin formation,
Angiotensin receptor regulation,
Role of the brain renin angiotensin system in hypertension.
Human:
Angiotensin and the progression of renal disease,
Renin system and atherosclerosis,
CV disease in renal insufficiency,
Clinical pharmacology of erythropoietins and other drugs in renal failure.
Clinical trial steering committees and coauthorships
AIPRI study (NEJM 1996),
HOPE study (NEJM 2000, Lancet 2000, Ann Int Med 2001), DIABHYCAR study (BMJ 2004),
4D study (NEJM 2005),
HOPE-TOO study (NEJM 2006),
ONTARGET study (NEJM 2008)
Renal-ONTARGET study (Lancet 2008) Renal-TRANSCEND study (Ann Int Med 2009)
pharmacokinetics of several ACE inhibitors in renal failure,
effects of several AT1-receptor antagonists in renal failure,
erythropoietin dosage schedules in renal failure.
Auszeichnungen
Awards and recognitions
Promotion (similar to D.Sc.) 1974, Univ. of Heidelberg
Habilitation (similar to Ph.D.) 1985, Univ. of Heidelberg
Paul Beiersdorf Award of the German Soc. of Internal Medicine 1988;
Prix Galien 1989;
Franz Gross Science Award, German Hypertension Soc 1999.
Past and present editorial boards and editorships
Kidney International; Nephrology, Dialysis and Transplantation; J Hypertension; Clinical Nephrology; Nieren- und Hochdruckkrankheiten, Herz und Gefässe.
Mitgliedschaften
Committees
- Officer, German Soc. Nephrology
- Officer, German Soc. Internal Medicine
- Ex-Member, Guideline commission, German Hypertension Soc
- Member, Quality Assurance, German Soc. Internal Medicine
- Ex-Member, Task force on Clinical trials of the International Soc. of Nephrology
Veröffentlichungen
- Mann JFE, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Dickstein K, Keltai M, Metsärinne K, Oto A, Teo KK, Yusuf S for the ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 372; 547 – 553, 2008
- Kunz R, Friedrich Ch, Wolbert M; Mann JFE. Effect of monotherapy and combination therapy with inhibitors of the renin-angiotensin system on proteinuria in renal disease. Ann Int Med 148: 30-48, 2008
- Schiffrin EL, Lipmann ML, Mann JFE.Chronic kidney disease: effects on the cardiovascular system. Circulation 116: 85 – 97, 2007
- Wanner Ch, V Krane, W Maerz , M Olschewski, JFE Mann, M Ruf, E Ritz. Statins in the treatment of patients with type 2 diabetes mellitus undergoing hemodialysis N Engl J Med 353: 238 – 248, 2005
- Mann JFE, EM Lonn, QL Yi, HC Gerstein, BJ Hoogwerf, J Pogue, J Bosch, GR Dagenais, S Yusuf. Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: results of the HOPE study. Kidney International 65: 1375 – 1380, 2004
- Pinkau T, KF Hilgers, R Veelken, JFE Mann. How does minor renal dysfunction influence cardiovascular risk and the management of cardiovascular disease? J Am Soc Nephrol15:517 – 523, 2004
- Mann JFE, HC Gerstein, QL Yi, EM. Lonn, BJ Hoogwerf, A Rashkow, S Yusuf Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study. J Am Soc Nephrol 2003; 14: 641-7
- Hilgers KF, A Hartner, M Porst, R Veelken, JFE Mann Angiotensin II type 1 receptor blockade prevents lethal malignant hypertension: relation to kidney inflammation. Circulation 104: 1436 – 1440, 2001
- Mann JFE, HC Gerstein, J Pogue, J Bosch, S Yusuf. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Int Med 134: 629 – 636, 2001
- Hilgers KF, A Hartner, R Veelken, JFE Mann. Monocyte chemoattractant protein-1 and macrophage infiltration in hypertensive kidney injury: role of the angiotensin II type 1 receptor. Kidney Intern, 58: 2408 – 2419, 2000
- Ritz E, JFE Mann. Renal angioplasty for lowering blood pressure. N Engl J Med, 342: 1042 – 1043, 2000
Prof. Dr. med. Johannes Mann:
"In Zusammenarbeit mit weltweiten Netzen von wissenschaftlich aktiven Nephrologen stellen wir sicher, dass Sie bei uns mit den modernsten Methoden auf dem aktuellen Stand des medizinischen Wissens behandelt werden."
